Literature DB >> 28657236

Letter: Regulating Hypothalamus Gene Expression in Food Intake: Dietary Composition or Calorie Density? (Diabetes Metab J 2017;41:121-7).

Bo Kyung Koo1.   

Abstract

Entities:  

Year:  2017        PMID: 28657236      PMCID: PMC5489503          DOI: 10.4093/dmj.2017.41.3.223

Source DB:  PubMed          Journal:  Diabetes Metab J        ISSN: 2233-6079            Impact factor:   5.376


× No keyword cloud information.
Jang et al. [1] reported that high saturated fatty acid (SFA) or n-3 polyunsaturated fat acid (PUFA) increased proopiomelanocortin (POMC) mRNA expression significantly compared with baseline. The expression of POMC was more prominently increased in SFA compared with PUFA. However, compared with carbohydrate (CHO)-rich diet, even SFA-rich diet lead to a significantly lower level of POMC mRNA expression. In contrast, in the case of neuropeptide Y (NPY), the mRNA expression was significantly lower in CHO-rich diet compared with SFA or PUFA-rich diet. Although Jang et al. [1] mentioned that the evidence regarding direct effect of different fatty acid diets on satiety in hypothalamus is sparse, previous studies have consistently reported that PUFA increases POMC expression by G-protein-coupled receptor 40 [23]. In the case of SFA, even though SFA decreased NPY mRNA expression [4], SFA could not alter POMC expression level [45], which is opposite to study of Jang et al. [1] that claimed SFA increased POMC mRNA level more prominently compared with PUFA. They should address the controversy between the previous studies and theirs. In addition, there have been studies on the association between glucagon-like peptide-1 (GLP-1) and dietary macronutrient composition. As is already well known, GLP-1 affects food intake [678]. Fat-rich meal increased GLP-1 response more prominently compared with isocaloric CHO-rich meals in human [9]. In addition, dietary fat composition also affects GLP-1 response: unsaturated fatty acids increase GLP-1 more than SFA [10]. Considering that GLP-1 reduces food intake by directly stimulating POMC/cocaine- and amphetamineregulated transcript (CART) neurons [67], there is a discrepancy between the previous studies [67] and findings of Jang et al. [1] that showed CHO-rich meal and SFA increased POMC expression level more compared with PUFA. Along with POMC stimulation, GLP-1 can also affect NPY; it indirectly inhibits neurons expressing NPY and agouti-related peptide (AgRP) via γ-aminobutyric acid (GABA)-dependent signaling [67]. Hypothalamic NPY and AgRP mRNAs are significantly increased by fasting, which can be significantly attenuated by GLP-1 treatment [8]. Considering the different effect on GLP-1 response according to dietary fatty acid composition, the effect of dietary fatty acid on POMC or NPY mRNA expression should be interpreted in terms of changes in GLP-1 level. Lastly, plasma glucose, free fatty acid, lipid, leptin, and ghrelin levels are very important factors in satiety regulation. I wonder if there were any differences in these levels in response to the interventions.
  10 in total

1.  n-3 Fatty Acids Induce Neurogenesis of Predominantly POMC-Expressing Cells in the Hypothalamus.

Authors:  Lucas F R Nascimento; Gabriela F P Souza; Joseane Morari; Guilherme O Barbosa; Carina Solon; Rodrigo F Moura; Sheila C Victório; Letícia M Ignácio-Souza; Daniela S Razolli; Hernandes F Carvalho; Lício A Velloso
Journal:  Diabetes       Date:  2015-10-28       Impact factor: 9.461

2.  Effects of dietary fat types on body fatness, leptin, and ARC leptin receptor, NPY, and AgRP mRNA expression.

Authors:  Hongqin Wang; Len H Storlien; Xu-Feng Huang
Journal:  Am J Physiol Endocrinol Metab       Date:  2002-06       Impact factor: 4.310

3.  Interaction between specific fatty acids, GLP-1 and insulin secretion in humans.

Authors:  C Beysen; F Karpe; B A Fielding; A Clark; J C Levy; K N Frayn
Journal:  Diabetologia       Date:  2002-10-02       Impact factor: 10.122

4.  Role of fat amount and type in ameliorating diet-induced obesity: insights at the level of hypothalamic arcuate nucleus leptin receptor, neuropeptide Y and pro-opiomelanocortin mRNA expression.

Authors:  X-F Huang; X Xin; P McLennan; L Storlien
Journal:  Diabetes Obes Metab       Date:  2004-01       Impact factor: 6.577

5.  A MUFA-rich diet improves posprandial glucose, lipid and GLP-1 responses in insulin-resistant subjects.

Authors:  Juan A Paniagua; Angel Gallego de la Sacristana; Esther Sánchez; Inmaculada Romero; Antonio Vidal-Puig; Francisco J Berral; Antonio Escribano; Maria José Moyano; Pablo Peréz-Martinez; José López-Miranda; Francisco Pérez-Jiménez
Journal:  J Am Coll Nutr       Date:  2007-10       Impact factor: 3.169

6.  Acute effects of glucagon-like peptide-1 on hypothalamic neuropeptide and AMP activated kinase expression in fasted rats.

Authors:  Sanghee Seo; Sunghee Ju; Hyunju Chung; Dahm Lee; Seungjoon Park
Journal:  Endocr J       Date:  2008-05-28       Impact factor: 2.349

7.  The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss.

Authors:  Anna Secher; Jacob Jelsing; Arian F Baquero; Jacob Hecksher-Sørensen; Michael A Cowley; Louise S Dalbøge; Gitte Hansen; Kevin L Grove; Charles Pyke; Kirsten Raun; Lauge Schäffer; Mads Tang-Christensen; Saurabh Verma; Brent M Witgen; Niels Vrang; Lotte Bjerre Knudsen
Journal:  J Clin Invest       Date:  2014-09-09       Impact factor: 14.808

8.  Various dietary fats differentially change the gene expression of neuropeptides involved in body weight regulation in rats.

Authors:  B Dziedzic; J Szemraj; J Bartkowiak; A Walczewska
Journal:  J Neuroendocrinol       Date:  2007-05       Impact factor: 3.627

9.  Regulating Hypothalamus Gene Expression in Food Intake: Dietary Composition or Calorie Density?

Authors:  Mi Jang; So Young Park; Yong Woon Kim; Seung Pil Jung; Jong Yeon Kim
Journal:  Diabetes Metab J       Date:  2016-12-16       Impact factor: 5.376

Review 10.  Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RAs) in the Brain-Adipocyte Axis.

Authors:  Bruno Geloneze; José Carlos de Lima-Júnior; Lício A Velloso
Journal:  Drugs       Date:  2017-04       Impact factor: 9.546

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.